INTRODUCTION
Early and aggressive therapy for rheumatoid arthritis (RA) with disease-modifying antirheumatic agents (DMARDs), glucocorticoids, and biologic agents is recommended by current treatment guidelines and supported by interventional studies with treat to target principles [1] . According to the current guidelines, diagnosis should be established as early as possible, therapy should be initiated immediately and escalated promptly to achieve low disease activity or remission. This goal should be reached within 3 to 6 months from diagnosis [1] .
The consequences of delays in adequate therapy have been well documented in the literature and have driven the development of aggressive guidelines for the early treatment of RA [2] [3] [4] [5] [6] [7] [8] [9] [10] . Over the last several years, it has been repeatedly demonstrated that postponements in the aggressive, early treatment of joint inflammation result in deleterious effects on radiographic and other outcomes; joint damage and disability ensue, uncontrolled disease activity further undermines patients' quality of life, and uncontrolled inflammation increases the risk of comorbidities and accelerates mortality [1, 11] . Importantly, it has been proven that achieving a low disease activity outcome is more likely when there are no delays in initiation of therapy and that a ''window of opportunity'' exists early after the onset of disease during which RA is more susceptible to treatment [12] .
Despite the above, several reports-mainly from European countries-show that only a minority of patients initiate disease-modifying therapy within the first few months of disease onset [13, 14] .
Similar reports evaluating in detail the frequency, extent and causes of delaying initiation of RA therapy in the United States (US) are not available. Our goal in the present study was to evaluate how frequently RA therapy is not instituted promptly, to describe the characteristics of patients who are not treated early upon diagnosis, and to evaluate the time interval until initiation of therapy. The largest disease-based RA registry in the US was used to address the aforementioned questions.
METHODS

Study Population
Patients included in this analysis were subjects with RA enrolled in the Corrona registry, a disease-based, multicenter, observational registry, which enrolls and follows longitudinally adult patients with a diagnosis of RA according to the treating rheumatologist. The Corrona US RA registry has previously been extensively described elsewhere [15] Approvals for data collection and analyses of the Corrona RA registry were obtained from local institutional review boards of participating academic sites and a central institutional review board for private practice sites.
Data Collection
The methods of data collection in Corrona have been extensively described previously [15] . In brief, data are collected from both patients and All data are first captured on paper questionnaires and then entered in an electronic data capture system. A quality control process is in place to ensure the collection of robust, reliable and validated data. First, the electronic data capture system used has a built-in capacity to automatically identify erroneous or discrepant data entries and immediately indicates the need for corrections. Subsequently, a dedicated quality control team reviews the entered data on a regular basis and communicates directly with the participant rheumatology practice to correct possible mistakes in data entry.
Statistical Analysis
All 
RESULTS
Demographic Characteristics
As shown in Table 1 , analysis of demographic, lifestyle, and anthropometric characteristics showed that patients who had not received any RA-directed therapy by the time of enrollment were more frequently smokers (20.1% vs. 15.6%, P\0.0001) and less frequently college level educated (43.7% vs. 55.1%, P\0.0001) compared to patients exposed to therapy.
Patients without history of RA-directed therapy were notably more frequently without medical insurance (5.8% vs. 2.3%, P\0.0001). There were no differences in age or racial distribution between the two populations.
Disease Characteristics
The comparison of disease characteristics between patients without history of RA-directed therapy at the time of enrollment compared to those who had a history of such therapy is shown in Table 2 . Patients without a history of RA-directed therapy had a shorter duration of RA disease (5.5 ± 9.0 years vs.
9.0 ± 9.7 years). However, almost half of those patients had established disease with a duration [1 year. The mean disease activity as measured by Clinical Disease Activity Index (CDAI) among Last, the percentage of patients without therapy but with moderate and high disease activity was higher ([60%) compared to those with prior therapy (51.3%). In addition, morning stiffness The Kaplan-Meier survival curves for the initiation of the various RA therapies are shown in Fig. 3 . Approximately, 50% of patients had not started any therapy until 12 months after enrollment to the registry and 25% of the patients have not started any therapy until 50 months after enrollment in the registry.
DISCUSSION
In this descriptive report, we estimated the prevalence of delays in initiation of RA therapy with data from the Corrona registrya large US-based cohort of patients with RA. We estimated the population persistently not receiving RA therapy and calculated the time to initiation of treatment. We described the characteristics of patients not treated promptly and compared them to patients on therapy at the time of enrollment to the Corrona registry.
According to our results, in an era where strong evidence supports the benefits of early initiation of disease-modifying therapy in RA [5] , there was still a minority of patients who did not receive appropriate treatment for a long [16] .
To the best of our knowledge, this is the first study evaluating the frequency and the duration of absence of RA-directed therapy in such a large patient population in the US.
Reports show that only a minority of patients are started on appropriate therapy in the first few months upon diagnosis but no reports have dealt with this particular fraction of patients who do not receive therapy for longer periods of time [17] [18] [19] . De Cock et al. [13] described a cohort of 156 patients with early RA and identified that only 21.6% of those patients were started on appropriate DMARD therapy within the first 12 weeks from disease onset.
The median time to initiation of appropriate therapy in this study cohort was 23 weeks.
Higher disease activity, presence of morning stiffness, and therapy by rheumatologist at an academic center were found to be determinants of earlier initiation of DMARD therapy. Our study, albeit did not investigate associations between patient or physician characteristics and therapy delays, followed a larger cohort of patients, included early but also established RA patients, and documented much longer delays in initiation of therapy.
Another European study by Potter et al. [14] identified 77 patients with early RA and investigated the reasons for delay in therapy by categorizing them as patient related [delay in presentation to their general practitioner (GP)], GP related, and rheumatologist related. The range of the delay between symptom onset to GP evaluation and then to rheumatologist examination ranged up to several years. Similar results were reported by Kiely et al. [20] where delays in initiation of therapy were due to referrals to secondary care in England. A study from France followed 627 patients with definite and probable RA and reported that 34% of the patients did not receive DMARDs 6 months after symptom onset; the primary reason for delay was related to uncertainty about diagnosis of RA [21] . Our study also reports long delays but did not aim to attribute the delays observed to specific causes.
Our patient population was based in the US with a health system structured in a different way compared to the European systems utilized in the studies mentioned above. In addition, the Corrona registry, although it collects extremely thorough information after enrollment, does not collect pertinent to therapy delays information for the period prior to enrollment to the registry. Nevertheless, our study reports information on a very large US-based patient cohort, followed for a long period of time. 
CONCLUSIONS
In conclusion, we demonstrated that the majority of patients enrolled in the Corrona registry are treated with RA-directed therapy.
However, there is still a minority of patients with RA who are not treated with disease-modifying therapy for long periods of time after diagnosis and that these patients did not have lower disease activity than those who were treated. A future analysis using matching methods should identify more detailed disease, patient, and physician factors related to such delays in therapy.
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